Johnson & Johnson: Johnson & Johnson Reports Strong Q2, Solid Growth in Vision Care

NEW BRUNSWICK, N.J.-Johnson & Johnson (NYSE: JNJ), a global healthcare company, announced its second-quarter 2026 financial results yesterday, reporting a 6.6 percent increase in sales to $25.3 billion. The company achieved 5.6 percent operational growth and 5.7 percent adjusted operational growth. Within the MedTech segment, which saw revenue rise 4.5 percent to $8.9 billion, the vision care category performed strongly, delivering 6 percent reported revenue growth (5.7 percent operationally). The company also raised its full-year 2026 outlook.